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Abstract
The proinflammatory cytokine Tumour Necrosis Factor (TNF)-a is implicated in a variety of skeletal muscle pathologies. Here,
we have investigated how in vitro cotreatment of skeletal muscle C2C12 cells with b-agonists modulates the TNF-a-induced
inflammatory program. We observed that C2C12 myotubes express functional TNF receptor 1 (TNF-R1) and b2-
adrenoreceptors (b2-ARs). TNF-a activated the canonical Nuclear Factor-kB (NF-kB) pathway and Mitogen-Activated Protein
Kinases (MAPKs), culminating in potent induction of NF-kB-dependent proinflammatory genes. Cotreatment with the b-
agonist isoproterenol potentiated the expression of inflammatory mediators, including Interleukin-6 (IL-6) and several
chemokines. The enhanced production of chemotactic factors upon TNF-a/isoproterenol cotreatment was also suggested
by the results from migrational analysis. Whereas we could not explain our observations by cytoplasmic crosstalk, we found
that TNF-R1-and b2-AR-induced signalling cascades cooperate in the nucleus. Using the IL-6 promoter as a model, we
demonstrated that TNF-a/isoproterenol cotreatment provoked phosphorylation of histone H3 at serine 10, concomitant
with enhanced promoter accessibility and recruitment of the NF-kB p65 subunit, cAMP-response element-binding protein
(CREB), CREB-binding protein (CBP) and RNA polymerase II. In summary, we show that b-agonists potentiate TNF-a action,
via nuclear crosstalk, that promotes chromatin relaxation at selected gene promoters. Our data warrant further study into
the mode of action of b-agonists and urge for caution in their use as therapeutic agents for muscular disorders.
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Introduction
Skeletal muscle atrophy is a devastating consequence of a large
number of diseases, including cancer and myopathies, but is also
apparent in physiological processes, such as aging or disuse.
Several lines of evidence indicate that inflammatory factors
contribute to the loss of skeletal muscle mass and function [1].
One of the cytokines that has been especially associated with the
development of skeletal muscle abnormalities is Tumour Necrosis
Factor (TNF)-a and elevated levels of TNF-a are apparent in
skeletal muscle wasting disorders [2]. TNF-a transduces its activity
via two different types of membrane-bound receptors, namely
TNF-receptor 1 (TNF-R1) and TNF-receptor 2 (TNF-R2), which
stimulate different cellular processes. TNF-R ligation leads to the
recruitment of receptor-specific adaptor proteins, which in turn
activate a cascade of protein kinases and several downstream
transcription factors, including the Nuclear Factor (NF)- kB [3].
NF-kB is the generic term for members of a family of
ubiquitously expressed transcription factors, that act as homo- or
heterodimers to regulate genes involved in immunity and
inflammation [4]. In the context of inflammatory gene expression,
the p65-p50 NF-kB heterodimer has been most intensively
studied. TNF-a induces the canonical NF-kB signalling pathway,
marked by activation of the IkB kinase b (IKKb) complex, which
phosphorylates the IkBa inhibitor proteins that, in resting cells,
sequester NF-kB in the cytoplasm. Phosphorylated IkBa is
ubiquitinylated and targeted for proteasomal degradation, allow-
ing NF-kB to migrate from the cytoplasm to the nucleus, where it
drives transcription of genes containing NF-kB-responsive ele-
ments [4]. Whereas NF-kB function has been mainly studied in
immune cells, recent reports have demonstrated a role for NF-kB
in a variety of other cell types, including skeletal muscle. For
instance, it was shown that interference with NF-kB activity, via
overexpression of IkB supersuppressor or p65 knock-out, reduces
inflammation and improves the regeneration process in different
skeletal muscle disease models [1,5].
The adrenergic receptors belong to the family of G-protein
coupled receptors (GPCRs) and skeletal muscle cells express
mainly the b2-adrenoreceptor (b2-AR) subtype [6]. b2-AR agonists
(b-agonists) are well known for their anabolic properties and
several in vivo studies support the therapeutic potential of b-
agonists in skeletal muscle wasting disorders [7-9]. Interestingly,
the existence of extensive crosstalk between b2-AR and TNF-R-
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e90649
mediated signalling cascades was documented in different cell
types and it was postulated that b-agonists have anti-inflammatory
effects, that can be, at least in part, explained by inhibition of NF-
kB activity [10–12]. Arguing against the anti-inflammatory effects
of b2-AR stimulation is the repeated observation, in different
model systems, that b-agonists potentiate the expression of the
prototypical inflammatory cytokine IL-6, a phenomenon that was
also reported in skeletal muscle cells in vivo and in vitro [13,14].
Recent genome-wide expression studies have yielded detailed
information on the individual effects of TNF-a or b-agonists on
the skeletal muscle transcriptome [15,16]. However, the effect of
controlled cotreatment of skeletal muscle cells with TNF-a and b-
agonists has, to our knowledge, never been investigated. In
addition, the molecular basis for the reported selective effect of b-
agonists on NF-kB dependent gene expression remains to be
elucidated. Therefore, we have investigated how b-agonists
modulate TNF-a-induced signalling cascades, focusing on the
NF-kB pathway and its target genes in C2C12 myotubes. As
opposed to previous reports in other cell types, we found no direct
inhibitory effects of b-agonists on the NF-kB cascade in C2C12
skeletal muscle cells. Instead, we found that the b-agonist
isoproterenol potently enhanced TNF-a-induced expression of
selected NF-kB target genes, such as interleukin-6 (IL-6) and
chemokine (C-X-C motif) ligand 5 (CXCL5). In addition, we
report that this selective potentiation is not mediated by
cytoplasmic modulation of NF-kB function, but instead relies on
atypical epigenetic events. Finally, in support of the physiological
relevance of our findings, the co-activation of b2-AR/TNF-Rs in
myotubes promoted the migration of undifferentiated myoblasts.
Materials and Methods
Reagents and Antibodies
Isoproterenol and Trichostatin A (TSA) were purchased from
Sigma Aldrich (St. Louis, MO, USA) and used at 10 mM and
100 nM, respectively. Murine TNF-a was a gift from the VIB
Department for Molecular Biomedical Research of Ghent
University (VIB-UGent, Gent, Belgium) and was used at
2000 IU/ml. Insulin-like growth factor-1 (IGF-1) was from
ImmunoTools (Friesoythe, Germany) and was used at 10 ng/ml.
Anti-b2-AR, anti-TNF-R1, anti-myogenin, anti-PARP, anti-P-H3-
Ser10, anti-CBP, anti-RNA polymerase II, anti-p65, anti-IkBa,
anti-P-CREB-Ser133 and anti-PKAc were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-P-p65-Ser536, anti-
P-ERK-Thr202/Tyr204, anti-P-JNK-Thr183/Tyr185, anti-P-
p38-Thr180/Tyr182, anti-P-MSK-1-Thr581, anti-Lamin A/C
and anti-CREB were from Cell Signaling Technology (Danvers,
MA, USA). Anti-Ac-H3-Lys27 and GAPDH were from AbCam
(Cambridge, UK). Anti-a-tubulin and anti-a-actin were from
Sigma-Aldrich. In figures, the expression ‘‘antibody anti-’’ was
substituted by the Greek letter ‘‘a-’’. AatII and HincII restriction
enzymes were obtained from New England BioLabs (Ipswich, MA,
USA).
Cell culture
Murine C2C12 cells (European Collection of Cell Cultures,
Salisbury, UK) were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM, Gibco by Life Technologies) supplemented
with 10% foetal bovine serum (Gibco by Invitrogen, Paisley, UK),
100 IU/ml penicillin and streptomycin (Gibco by Life Technol-
ogies, Grand Island, NY, USA) (referred to herein after as growth
medium or GM). Cells were cultured in an incubator at 37uC in a
humidified atmosphere containing 5% CO2. Cells were passaged
using 0.05% Trypsin+EDTA (Gibco by Life Technologies). In
experiments using myoblasts, cells were seeded at 200000 cells/
well in a 6-well format and GM was substituted by starvation
medium (DMEM containing 1% foetal bovine serum, 100 IU/mL
penicillin and streptomycin, referred as SM) for 24 hours. In
experiments using myotubes, cells were seeded at 300000 cells/
well in a 6-well format and GM was substituted by differentiation
medium to induce differentiation (DMEM containing 2% horse
serum, 100 U/ml penicillin and streptomycin, referred as differ-
entiation medium or DM). To obtain myotubes, cells were
cultured for 5 days in DM.
RNA isolation, cDNA synthesis and Real-Time
Quantitative PCR (RT-qPCR)
Total RNA was extracted with the RNeasy Mini Kit (Qiagen,
Venlo, Netherlands). Reverse transcription was performed on
0.5 mg of total mRNA using the PrimeScript RT reagent kit from
Takara Bio Inc. (Shiga, Japan). For real time cDNA amplification
we used the Roche SYBR Green Mastermix (Roche Applied
Science, Penzberg, Germany) and primers listed in Table S1.
Fluorescence was monitored using the Light Cycler 480II (Roche).
A serial dilution of a representative cDNA sample was used to
generate a standard curve and determine the efficiency of the PCR
reaction for all primer sets which was used in the subsequent
calculation of relative mRNA inputs. Expression of each gene was
normalized to expression of the HPRT house-keeping gene and
results are presented as fold induction compared to untreated cells.
For clarity the Y-axis is interrupted in some cases.
Luciferase reporter assay
The NF-kB-luciferase reporter plasmid and the b-galactosidase
control constructs have been described elsewhere [17]. The CRE-
luciferase reporter plasmid was from Stratagene (LaJolla, CA).
Transient transfection was performed using the Neon Transfection
system (Invitrogen), according to the manufacturer’s instructions
for the murine C2C12 cell line. Briefly, cells were transfected with
1 mg of luciferase reporter constructs harbouring a consensus NF-
kB site or CREB binding site and seeded to semi-confluence in 24-
well plates. Cells were cotransfected with a b-galactosidase
reporter construct (200 ng) containing the constitutively active
pPGK promoter to correct for transfection efficiency. Following
transfection, cells were differentiated for 5 days. Subsequently,
cells were induced with isoproterenol and/or TNF-a for 6 hours.
Total lysate was then incubated with luciferase substrate and
luminescence was measured on a TopCount luminometer
(PerkinElmer Life Sciences, Canberra-Packard, Waverley, UK).
Luciferase activity was expressed as fold induction (treated/
untreated) upon normalisation for transfection efficiency.
Isolation of cellular proteins
For preparation of total protein lysates, cells were washed with
ice-cold Phosphate Buffered Saline (PBS) and subsequently lysed
in RIPA lysis buffer (200 mM NaCl, 50 mM Tris HCl pH 8.0,
0.05% SDS, 2 mM EDTA, 1% NP40, 0.5% Na-Deoxycholate,
2 mM Na2MoO4 and 10 mM NaF, Complete Protease Inhibitor
Cocktail (Roche)) or in SDS sample buffer (10% glycerol,
62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.5% b-mercaptoethanol
and Bromophenol Blue).
For isolation of nuclear proteins, cells were washed with PBS,
PBS with 2 mM Na2MoO4 and 10 mM NaF and buffer HB
(20 mM Hepes pH 7.5, 10 mM NaF, 2 mM Na2MoO4, 0.2 mM
EDTA pH 7.5). After aspiration of the washing buffer, lysis buffer
(20 mM Hepes pH 7.5, 10 mM NaF, 2 mM Na2MoO4, 0.2 mM
EDTA pH 7.5, 0.05% NP40, Complete Protease Inhibitor
b-Agonists Modulate Skeletal Muscle Inflammation
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Cocktail (Roche)) was added. Subsequently, cells were scraped and
collected. Samples were centrifuged at 17900 g for 1 minute in
4uC. The pellet was recovered and resuspended in Resuspension
Buffer (20 mM Hepes pH 7.5, 0.1 mM EDTA pH 7.5, 5 mM
NaF, 1 mM Na2MoO4, 20% glycerol) supplemented with the
Complete Protease Inhibitor Cocktail (Roche). Next, equal volume
of salt buffer (20 mM Hepes pH 7.5, 1.6 M NaCl, 0.1 mM EDTA
pH 7.5, 5 mM NaF, 1 mM Na2MoO4, 20% glycerol, Complete
Protease Inhibitor Cocktail (Roche)) was added. Samples were
incubated for 30 minutes in the shaker at 4uC and subsequently
centrifuged at 17900 g for 10 minutes at 4uC. Samples were next
diluted to equal protein concentration (determined via BioRad
protein assay) and 5x concentrated SDS sample buffer was added.
The extracts were used subsequently for Western blotting analysis.
Protein contents of RIPA lysates and nuclear extracts were
determined using the Bio-Rad protein assay according to
manufacturer’s instructions. Samples were next diluted to equal
protein concentration and 5x concentrated SDS sample buffer was
added. The extracts were used subsequently for Western blotting
analysis.
Western blotting
10 mg of nuclear proteins, 25 or 50 mg RIPA protein lysates or
25 ml of SDS sample buffer protein lysates were resolved using
SDS-PAGE on 10% or 12% polyacrylamide gels, transferred to
nitrocellulose membranes (Amersham, Dubendorf, Switzerland)
and analysed by Western blotting. Briefly, membranes were
incubated with Blocking Buffer (LICOR Biosciences, Lincoln, NE,
USA) diluted with PBS in a 1:1 ratio. Subsequently, membranes
were probed with primary antibody diluted 1:1000 in Blocking
Buffer diluted 1:1 with PBS containing 0.1% Tween (PBS-T).
After washing in PBS-T, DyLight secondary antibody (Pierce,
Rockford, IL, USA) was applied diluted 1:10000 in Blocking
Buffer/PBS-T (1:1). The membranes were then washed in PBS-T
and detection was performed using the Odyssey Imaging System
(Licor). Subsequently, the membranes were reprobed with Actin,
Tubulin, GAPDH, Lamin A/C or PARP antibodies to verify
equal loading. Densitometric analysis averaging the results from
independent Western blotting experiments was performed using
ImageJ.
Chromatin accessibility assay via Real-Time PCR (CHART-
PCR)
The nuclease accessibility technique was performed as follows:
cells were washed in PBS, scraped and collected by centrifugation
at 453 g for 5 minutes at 4uC. Next, cells were resuspended in
buffer A (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl2,
0.3 M sucrose) and incubated for 10 minutes at 4uC. Next, equal
volume of lysis buffer was added (10 mM Tris pH 7.5, 10 mM
NaCl, 3 mM MgCl2, 0.3 M sucrose, 0.4% NP40 and 2 mM Na-
butyrate) and cells were incubated for 10 minutes at 4uC. After
centrifugation at 240 g for 5 minutes at 4uC, chromatin was
resuspended in buffer R (10 mM Tris pH 7.5, 10 mM NaCl,
3 mM MgCl2, 1 mM Na-butyrate) digested for 30 min at 37uC
with restriction enzymes in the buffer recommended by the
manufacturer (New England BioLabs). Reactions were terminated
by the addition of 26Proteinase K buffer (100 mM Tris, pH 7.5,
200 mM NaCl, 2 mM EDTA, 1% SDS). Following proteinase K
(Qiagen) and RNase A (Qiagen) treatment, genomic DNA (gDNA)
was extracted using the phenol/chloroform/isoamyl alcohol
(Sigma-Aldrich) method and subsequently resuspended in sterile
water after ethanol precipitation. Purified gDNA (10 ng) was used
for RT-PCR. Primers were designed to amplify sequences within
the murine IL-6 promoter (Table S1). A serial dilution of a
representative gDNA sample was used to generate a standard
curve and determine the efficiency of the PCR reaction for all
primer sets and to calculate the relative gDNA concentration
([gDNA]) of the samples. Data are presented as chromatin
opening which was defined as the ratio of [gDNA] of samples
digested with restriction enzymes over [gDNA] of undigested
samples: Chromatin opening = [gDNA]digested/[gDNA]undi-
gested.
Chromatin immunoprecipitation (ChIP)
For ChIP experiments, protein/DNA complexes were cross-
linked in cellulo by adding formaldehyde directly to the culture
medium to a final concentration of 1%. After 10 minutes, glycine
was added to a final concentration of 125 mM for another 10
minutes. Cells were washed, scraped and collected. Pellets were
lysed in FA lysis buffer (0.1% SDS, 1% Triton X-100, 150 mM
NaCl, 1 mM EDTA, 20 mM Tris pH 8.0) supplemented with
Complete Protease Inhibitor Cocktail (Roche). Cells were soni-
cated using the Diagenode Bioruptor (Lie`ge, Belgium) at high
settings (8 min, 30 s on/30 s off, samples cooled on ice and repeat
of the 8 minute cycle). Sonicated lysates were mixed in 1:5 ratio
with incubation buffer (0.15% SDS, 1% Triton X-100, 150 mM,
1 mM EDTA, 20 mM HEPES-KOH pH 7.5) followed by
immunoprecipitation with 5 mg of anti-p65, anti-polymerase
RNA II, anti-P-H3 Serine 10, anti-Ac-H3 Lys27, anti-CBP or
anti-CREB using Protein A Sepharose 4 Fast Flow beads
(Amersham). Samples were decrosslinked overnight at 65uC. All
samples were treated with 50 mg/ml of RNase A and 100 mg/ml
of Proteinase K. Immunoprecipitated genomic DNA (gDNA) was
purified with the QiaQuick PCR purification kit (Qiagen) and
subsequently quantified by Real Time PCR using the Roche
SYBR Green Mastermix (Roche). Primers used for amplification
of the IL-6 promoter and GAPDH control region are listed in
Table S1. Quantitative PCR was performed on the Light Cycler
480II (Roche). Determination of [gDNA] in the input and
immunoprecipitated samples (IPs) was performed as for
CHART-PCR. Data are presented as the percentage (%) of
[gDNA] in the IPs as compared to the [gDNA] in the
corresponding input sample: %IP = ([gDNA]IP/[gDNA]input)
6100.
Medium swap and migration assay
To investigate the influence of myotube-secreted factors on
myoblast migration, a medium swap, followed by a migration
assay, was performed. Conditioned media were prepared from
untreated myotubes or myotubes treated with isoproterenol and/
or TNF-a for 60 minutes. Subsequently, cells were washed twice
with DMEM to remove the remaining inducers and incubated
with serum-free DMEM for 24 hours to collect conditioned media
with secreted factors. Conditioned media were filtered on 0.22 mm
pore membranes (MILLEX GS, MF-Millipore MCE Membrane)
and applied to myoblasts. As a positive control, IGF-1, dissolved in
serum free DMEM, was used. Myoblasts were seeded in GM
(20000 cells/well) on a collagen coating (25 mg/mL rat tail
monomeric collagen type I; BD Biosciences, Two Oak Park,
Bedford, MA, USA) in wells of a 96-well plate. A cell-free area was
generated in the middle of the well using stoppers, according to the
ORIS cell migration protocol (ORIS; Platypus Technologies).
After 5 hours of cell adhesion, stoppers were removed, GM was
aspirated, 100 ml of conditioned media was applied and cells were
allowed to migrate for 24 hours into the cell-free central zone.
Phase-contrast time-lapse movies were recorded for 24 hours with
an interval of 10 minutes using a 10x UPlanFL objective (N.A.
0.30) on a CellM system with a IX81 microscope (Olympus). Four
b-Agonists Modulate Skeletal Muscle Inflammation
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to eleven replicates were tested per condition and three
independent experiments were performed. The area covered by
the cell layer (that increases due to migration towards the central
zone) was determined in time using customized software
(CELLMIA, unpublished data). Cell migration velocity (mean of
n replicates as indicated) is determined based on the slope of linear
fit on the area over time data. The relative migration efficiency is
the normalized cell velocity over different independent experi-
ments.
Statistical analysis
Statistical analysis was performed using Student’s t-test or one-
way ANOVA followed by Bonferroni’s multiple comparison test
with Graphpad Prism 4 software (Graphpad Software Inc.).
Migration data are presented as mean 6 standard error and
statistical analysis was performed using Wilcoxon pairwise
comparison with Bonferroni correction for multiple testing in R
version 2.15.2 (The R Foundation for Statistical Computing).
Results were considered significant when p-value ,0.05.
Results
C2C12 myotubes express TNF-R1 and b2-ARs
The murine C2C12 cell line is a well-established in vitro model
for the study of molecular interactions occurring in skeletal muscle
cells at different steps of myogenesis [18,19]. We first investigated
the expression levels of b2-ARs and TNF-R1/2 in undifferentiated
myoblasts versus differentiated myotubes. Progression in myogen-
esis was confirmed by measuring myogenin expression (Figure
S1A). We observed that myogenic differentiation was associated
with augmented mRNA levels of TNF-R1 as well as b2-AR, as
shown in Figure 1A and B, respectively. At the protein level, we
did, however, not detect more TNF-R1 in myotubes as compared
to myoblasts. Also, we did not detect an increase in the
immunoreactive signal representing the monomeric b2-AR, which
has a molecular weight of approximately 50 kDa. We did however
observe that multiple high-molecular weight immunoreactive
bands appear upon myogenic differentiation of C2C12 cells
(Figure 1B). To corroborate that the high-molecular weight
immunoreactivities indeed represent b2-ARs, we overexpressed a
hemagglutinin (HA)-tagged b2-AR (b2-AR-HA) in HEK-293T
cells, which do not express endogenous b2-AR. Like in C2C12
cells, we found higher molecular weight bands that react with the
anti-b2-AR antibody. In addition, we found that these bands
overlap with immunoreactivities detected with anti-HA, indicating
they indeed derive from b2-AR species, and probably represent
post-translationally modified or oligomeric forms of the b2-AR
(Figure S1B) [20,21]. In conclusion, these data indicate C2C12
myotubes express both TNF-R1 and b2-AR protein and indicate
the expression of variant b2-AR species is upregulated in the
course of myogenesis. Given that myotubes have been shown to
secrete a wide variety of mediators when subjected to pro-
inflammatory stimuli [22], and as C2C12 myotubes express both
TNF-R1 and b2-AR2, we have used C2C12 myotubes for further
experiments into b2-AR2/TNF-R1 crosstalk.
Effect of b-agonist cotreatment on TNF-a-induced, NF-
kB-dependent, inflammatory gene expression in skeletal
muscle cells
In physiological and pathological circumstances, such as during
an acute boost of exercise or in chronic inflammatory disease,
skeletal muscle cells express a number of NF-kB-dependent
cytokines and other inflammatory markers [1,23]. Here, we
performed a RT-qPCR analysis to assess how b-agonist cotreat-
ment modulates the expression of well-known NF-kB target genes
with a previously demonstrated role in skeletal muscle homeostasis
[15,23,24]. The presence of NF-kB binding sites in the promoters
of the selected genes was confirmed by a bioinformatics analysis
using P-Scan (Table S2). For each gene, the promoter region of
500 bp upstream to the Transcription Starting Site was investi-
gated with the Transcription Factor Binding Sites matrices
available in the TRANSFAC databases.
We found that in C2C12 myotubes, TNF-a significantly
induced the expression of intercellular adhesion molecule 1
(ICAM-1), NF-kB inhibitor alpha (IkBa), chemokine (C-C motif)
ligand 2 (CCL2) and chemokine (C-C motif) ligand 5 (CCL5),
whereas it had modest yet insignificant effects on the expression of
interleukin-6 (IL-6) and chemokine (C-X-C motif) ligand 5
(CXCL5) (Figure 2). We found no clear effects of TNF-a on the
expression of interleukin-7 (IL-7), interleukin-15 (IL-15) and Brain
derived neurotrophic factor (BDNF) (Figure S2). Isoproterenol by
itself did not significantly affect the expression of any of the
investigated genes, but had a mild positive effect on the expression
of CXCL5 and IL-6. Interestingly, we found that isoproterenol
cotreatment did not significantly modulate TNF-a-induced CCL5
and IkBa transcription (Figure 2D, F), but enhanced the effect of
TNF-a on the expression of CCL2 and ICAM-1 (Figure 2C, E)
and induced a pronounced synergy for IL-6 and CXCL5
(Figure 2A, B, Table 1). Overall, the effect of TNF-a on the
expression of the selected genes was rapid and transient, peaking
after 2 hours of treatment and then rapidly declining, and these
kinetics were not modulated by isoproterenol cotreatment. Only
CCL5 mRNA levels peaked at 5 hours, both upon TNF-a and
TNF-a and isoproterenol cotreatment, and were maintained even
after 16 hours induction (Figure 2 D). We concluded that in
C2C12 myotubes a subset of NF-kB-dependent genes exists with
different responses to TNF-a or costimulation with isoproterenol.
Cytoplasmic signalling crosstalk upon b2-AR/TNF-R co-
activation in C2C12 myotubes
Because isoproterenol enhanced the expression of several typical
NF-kB target genes, we explored what could be the molecular
basis of these effects. Upon binding to its receptor(s), TNF-a
triggers the canonical NF-kB cascade, initiated by IKKb
activation, IkBa degradation, phosphorylation of the NF-kB p65
subunit on serine 536 and its subsequent translocation from the
cytoplasm to the nucleus [4]. As evaluated by Western blotting, we
detected canonical NF-kB activation in C2C12 myotubes treated
with TNF-a. We observed rapid phosphorylation of p65 on serine
536, degradation of IkBa (Figure 3 A), and nuclear translocation
of p65 (Figure 3B). In line with this, TNF-a also induced an NF-
kB reporter gene transiently transfected in C2C12 cells
(Figure 3C). Isoproterenol treatment by itself had no effect on
any of these aspects of canonical NF-kB activation and did not
modulate the effects of TNF-a (Figure 3A-C).
In addition to the NF-kB pathway, TNF-a triggers activation of
Mitogen Activated Protein Kinases (MAPKs) and Mitogen and
Stress-activated Kinase 1 (MSK-1) which cooperate with NF-kB in
driving inflammation [17,25]. We found that in C2C12 myotubes,
TNF-a activated JNK (Jun N-terminal kinase), ERK (Extracellular
signal-regulated kinase) and p38 MAPKs and MSK-1 (Figure 3D-
G). Isoproterenol by itself did not have significant effects on the
phosphorylation of any of the MAPKs or MSK-1. Isoproterenol
slightly inhibited TNF-a-induced phosphorylation of ERK, JNK
and MSK-1, whereas it did not significantly affect TNF-a-induced
p38 MAPK activation (Figure 3D–G). Collectively, this suggests
that the potentiation of TNF-a-induced gene expression by
b-Agonists Modulate Skeletal Muscle Inflammation
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isoproterenol is unlikely to be mediated by cytoplasmic modulation
of NF-kB activity (Figure 2).
The canonical signalling pathway that is induced by b2-AR
triggering is the protein kinase A (PKA)/ cAMP-response element-
binding protein (CREB) cascade. We detected rapid phosphory-
lation of CREB on serine 133 in cells treated with isoproterenol as
well as TNF-a. Combined treatment did not further potentiate
CREB phosphorylation (Figure 4A). Nuclear translocation of the
PKA catalytic subunit (PKAc) was only detected in cells treated
with isoproterenol and not in TNF-a-treated cells (Figure 4B).
Whereas both TNF-a and isoproterenol induced CREB phos-
phorylation, only isoproterenol-activated CREB was able to
induce a CRE reporter gene in C2C12 cells (Figure 4C). TNF-a
cotreatment did not modulate isoproterenol-induced CRE activity.
b2-AR/TNF-R cotreatment induces chromatin
modifications required for efficient recruitment of NF-kB
Because we did not detect any cytoplasmic b2-AR/TNF-Rs
crosstalk events that could explain the observed synergy, we next
explored nuclear crosstalk. We used the IL-6 gene, a prototypical
NF-kB target gene, with known function in skeletal muscle, and
the most potently affected gene in our RT-qPCR analysis, as a
model system. The IL-6 gene has a complex promoter architecture
and, among others, contains functional transcription factor
binding sites for NF-kB and CREB [17,26].
The accessibility of a gene’s promoter to transcription factors is
reflected in its susceptibility to nuclease digestion. In CHART-
PCR, this feature is exploited and the accessibility of a selected
DNA sequence is determined by digesting chromatin using
nucleases and then quantifying the amount of remaining uncut
gDNA in the digested chromatin sample via qPCR. Here, we
digested the proximal IL-6 gene promoter using two restriction
enzymes (AatII, HincII) that cut in the proximal IL-6 promoter, in
the vicinity of CREB and NF-kB binding sites respectively. Then,
we amplified the sequence of interest via qPCR, using primers that
recognise the sequence flanking the restriction enzyme recognition
sites (Figure 5A). Results were normalised as explained in the
Materials and Methods section and expressed as chromatin
opening. We found that the IL-6 promoter is susceptible to
digestion with the AatII and HincII restriction enzymes, only upon
cotreatment with TNF-a and isoproterenol (Figure 5B). As
Figure 1. Expression of TNF-R1 and b2-AR in C2C12 myoblasts and myotubes. The basal expression of TNF-R1 (A) and b2-AR (B) mRNA and
protein was compared in C2C12 myoblasts versus myotubes using RT-qPCR and Western blotting. RIPA lysates were prepared and equal amounts of
protein were loaded on gel. Bar charts represent average 6 SD of densitometric analysis of three independent experiments. (For the b2-AR Western
blot only the monomeric form of the receptor was densitometrically quantified.) A representative blot is shown. (*) significantly different from
myoblasts using student’s t-test.
doi:10.1371/journal.pone.0090649.g001
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expected, no chromatin opening was apparent, at an irrelevant
region (not containing restriction sites for AatII and HincII) of the
IL-6 gene (Figure 5B).
Covalent modification of histone tails is a crucial event in the
regulation of chromatin dynamics. In particular enhanced
acetylation of histone H3 has been detected at transcriptionally
active chromatin [27]. To investigate whether histone acetylation
is implicated in IL-6 transcription induced by TNF-a/isoproter-
enol cotreatment, we first explored how the histone deacetylase
(HDAC) inhibitor Trichostatin A (TSA) affects IL-6 transcription.
Remarkably, we found that TSA, at subcytotoxic dose (100 nM),
almost completely abrogated IL-6 transcription triggered by
isoproterenol, TNF-a or the combination of both, indicating IL-
6 transcription is inhibited, rather than enhanced by histone
acetylation (Figure 5C). To assess histone H3 acetylation at the IL-
6 promoter, we performed ChIP using an antibody recognising
histone H3 acetylated at the Lys 27 residue, a modification for
which the association with transcriptional activation is well
established [28-30]. We found that, at the IL-6 promoter, histone
H3 carried a constitutive acetylation mark at Lys 27, that was not
significantly enhanced upon isoproterenol and/or TNF-a treat-
ment (Figure S3A). We also failed to detect enhanced histone H3
acetylation using a pan acetyl-histone-H3 antibody (data not
shown). The efficiency of the dose of TSA that we used to promote
histone acetylation was confirmed by the detection of histone H3
Lys 27 acetylation in TSA-treated C2C12 cells by confocal
microscopy (Figure S3B).
We found that isoproterenol stimulated PKA nuclear entry in
C2C12 cells, while TNF-a promoted phosphorylation of MSK-1.
Intriguingly, both PKA and MSK-1 have been shown to trigger
phosphorylation of histone H3 on serine 10, a modification
associated with chromatin relaxation and transcriptional activity
[31,32]. Via ChIP analysis, we detected very modest histone H3
phosphorylation at the IL-6 promoter upon isoproterenol stimu-
lation that was significantly potentiated upon cotreatment of
C2C12 cells with TNF-a (Figure 5D). Finally, we observed that
isoproterenol promoted recruitment of CREB, CREB-binding
protein (CBP) and RNA polymerase II to the IL-6 promoter,
whereas TNF-a induced recruitment of NF-kB p65. Combined
treatment with TNF-a and isoproterenol moreover potentiated the
recruitment of p65, CBP and RNA polymerase II to the IL-6
promoter (Figure 5E-H). Isoproterenol-induced CREB recruit-
ment was not modulated by TNF-a cotreatment. The specificity of
Figure 2. Effect of isoproterenol/TNF-a cotreatment on NF-kB-dependent gene expression in C2C12 myotubes. Expression of
inflammatory markers was measured by RT-qPCR after 2, 5 and 16-hours induction with vehicle (veh), isoproterenol (iso) and/or TNF-a (TNF) in C2C12
myotubes. Fold induction for each gene was calculated versus veh control at the corresponding time point. Results represent average 6 SD of three
independent experiments. Statistical significance was determined via ANOVA followed by Bonferroni’s multiple comparison test. (*) Significantly
different from veh. (**) Significantly different from TNF. (***) Significantly different from iso.
doi:10.1371/journal.pone.0090649.g002
Table 1. Synergy factors upon combined isoproterenol/TNF-
a treatment in C2C12 skeletal muscle.
Synergy Factor
2 h 5 h 16 h
Mean St Dev Mean St Dev Mean St Dev
IL-6 8.80 (*) 3.13 1.48 0.74 0.68 0.31
CXCL5 3.98 (*) 1.20 2.07 0.51 1.38 0.37
CCL2 1.48 0.38 1.59 0.39 0.92 0.21
CCL5 1.52 0.44 1.22 0.28 1.14 0.30
ICAM-1 1.66 1.06 1.35 0.80 0.18 0.10
IkBa 0.93 0.46 0.77 0.29 0.40 0.16
The strength of the synergies was calculated by dividing the relative mRNA
levels upon TNF-a/isoproterenol induction (Z) by the sum of the relative mRNA
levels after individual TNF-a (X) and isoproterenol (Y) induction (i.e. Z/(X+Y)). (*)
Significant synergy meaning Z/(X+Y) significantly larger than X+Y.
doi:10.1371/journal.pone.0090649.t001
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the observed responses is indicated by the fact that we did not
detect any of the observed responses at an irrelevant housekeeping
gene (GAPDH) or using aspecific antibodies or beads only for the
immunoprecipitation (Figure S3A, C-H).
These results show that only combined stimulation with TNF-a
and isoproterenol leads to chromatin remodelling at the IL-6
promoter.
Myotube-derived cytokines induce migration of
myoblasts
Recent literature shows that, upon contraction or inflammation,
skeletal muscle cells express several cytokines with chemotactic
properties [24,33]. Because we observed that cotreatment of
C2C12 myotubes with isoproterenol enhanced transcription of
several TNF-a-induced cyto-/chemokines that are known to
modulate the migratory properties of cells, we investigated
whether these factors induced migration of undifferentiated
C2C12 myoblasts. It was reported that C2C12 myoblasts exhibit
spontaneous mobility, which can be further stimulated by IGF-1
[33]. To analyse whether TNF-a/isoproterenol cotreatment
induces the production of chemotactic factors by myotubes, we
performed migration assays using myoblasts treated with myotube-
conditioned medium. IGF-1 stimulation was used as a positive
control. As shown in Figure 6 and Figure S4, myoblast cells treated
with conditioned medium from myotubes stimulated with only
TNF-a or isoproterenol displayed a modest, albeit significant
increase in myoblast migration efficiency compared to the control
condition. Importantly, myoblasts treated with conditioned
medium derived from myotubes, which were stimulated with the
combination of TNF-a and isoproterenol, migrated significantly
faster than those treated with conditioned medium from myotubes
treated with only TNF-a or isoproterenol (Figure 6C, Figure S4).
This indicates that the conditioned medium of the cotreated
myotubes has a stronger chemotactic potential on undifferentiated
myoblasts.
Discussion
The devastating role of TNF-a and NF-kB in skeletal muscle
inflammation and atrophy is well documented [2,5]. Here, we
investigated whether and how b-agonists, that are known for their
anabolic and anti-inflammatory properties, modulate the effects of
TNF-a on the expression of inflammatory factors in skeletal
muscle cells.
Figure 3. Effect of isoproterenol on TNF-a-induced NF-kB and MAPKs activation in C2C12 myotubes. (A) Kinetics of IkBa degradation
and increase in phosphorylation of p65 at serine 536. After veh, iso and/or TNF treatment cells were lysed in SDS sample buffer and analysed via
Western blotting. Bar charts represent average 6 SD of densitometric analysis of three independent experiments. A representative blot is shown. (B)
Kinetics of p65 nuclear translocation. After veh, iso and/or TNF treatment, nuclear extracts were prepared and analysed via Western blotting. A
representative blot from two independent experiments is shown. (C) Induction of NF-kB reporter gene activity. C2C12 myotubes, transfected with the
kB-luciferase reporter plasmid, were treated with veh, iso and/or TNF for 6 hours, before analysis of luciferase production. Fold induction was
calculated versus veh control. Results represent average 6 SD of three independent experiments. (D–G) Increase in phosphorylation of ERK (D), JNK
(E), p38 (F) and MSK-1 (G). After induction of C2C12 myotubes for 15 minutes with veh, iso and/or TNF, cells were lysed in SDS sample buffer and
analysed via Western blotting. Bar charts represent average 6 SD of densitometric analysis of three independent experiments. A representative blot
is shown. Statistical significance was determined via ANOVA followed by Bonferroni’s multiple comparison test (*) Significantly different from veh.
(***) Significantly different from iso.
doi:10.1371/journal.pone.0090649.g003
Figure 4. Effect of isoproterenol/TNF-a cotreatment on activation of the PKA/CREB cascade. (A) Increase in phosphorylation of CREB at
serine 133. After induction of C2C12 myotubes for 15 minutes with veh, iso and/or TNF, cells were lysed in SDS sample buffer and analysed via
Western blotting. Bar charts represent average 6 SD of densitometric analysis of three independent experiments. A representative blot is shown. (B)
Effect on nuclear translocation of PKAc. After veh, iso and/or TNF treatment for 15 min, nuclear extracts were prepared and analysed via Western
blotting. Bar charts represent average6 SD of densitometric analysis of three independent experiments. A representative blot is shown. (C) Effect on
the activation of CREB. C2C12 myotubes, transfected with the CRE-luciferase reporter plasmid, were treated with veh, TNF and/or iso for 6 hours,
before analysis of luciferase production. Fold induction was calculated versus veh control. Results represent average 6 SD of three independent
experiments. Statistical significance was determined via ANOVA followed by Bonferroni’s multiple comparison test (*) Significantly different from veh.
(***) Significantly different from iso.
doi:10.1371/journal.pone.0090649.g004
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Figure 5. TNF-a/isoproterenol cotreatment induces chromatin remodelling and histone H3 modifications at the IL-6 promoter in
C2C12 myotubes. (A) Schematic representation of the localisation of CREB- and NF-kB-responsive elements in the IL-6 promoter. Relative position
of the recognition sites for AatII and HincII and primers used in the restriction enzyme accessibility assay via Real Time PCR (CHART-PCR) are
indicated. (B) TNF/iso cotreatment promotes accessibility of the IL-6 promoter. C2C12 cells were treated for 2 hours with veh, iso and/or TNF.
Chromatin opening of the promoter region was determined by CHART-PCR as detailed in Materials and Methods. Results represent average 6 SD of
three independent experiments. (C) Effect of TSA, a histone deacetylase inhibitor, on IL-6 transcription. C2C12 cells were treated for 2 hours with
combinations of veh, TSA, iso and/or TNF. mRNA levels of IL-6 were determined via RT-qPCR. Results represent average 6 SD of three independent
experiments. (D) TNF/iso cotreatment enhances phosphorylation of histone H3 at the IL-6 promoter. C2C12 cells were treated with veh, iso and/or
TNF for 2 hours. Phosphorylation of histone H3 at serine 10 was determined via ChIP. Results represent average 6 SD of three independent
experiments. (E-H) Effect of TNF and/or iso treatment on the recruitment of NF-kB, CREB, CBP and RNA polymerase II to the IL-6 promoter. C2C12 cells
were treated with veh, iso and/or TNF for 2 hours. Recruitment of NF-kB p65, CREB, CBP and RNA polymerase II was measured via ChIP. Results
represent average 6 SD of three independent experiments. (*) Significantly different from veh. (**) Significantly different from TNF. (***) Significantly
different from iso.
doi:10.1371/journal.pone.0090649.g005
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We used the murine C2C12 cell line as in vitro model system and
found that the expression of b2-ARs was much more prominent,
both at the mRNA and protein level, in differentiated myotubes as
compared to undifferentiated myoblasts, indicating myotubes
would be more susceptible to regulation by b2-AR-agonists. In
agreement with this finding, elevated expression of the b2-AR was
reported in regenerating myofibers after injury [7]. Whereas we
also observed increased TNF-R1 expression at the mRNA level,
this was not reflected at the protein level. Enhanced TNF-R1
mRNA levels were previously reported in regenerating myofibers,
but the level of protein in the latter study was not investigated [34].
In another study decreased activation of NF-kB upon TNF-a
treatment was observed upon myogenesis [35], but in this study
TNF-R1 expression levels were not investigated and the dimin-
ished response could also be due to post-receptor regulatory
mechanisms [36]. Our data suggest that in C2C12 cells TNF-R1
protein levels are not regulated upon myogenic differentiation,
despite clear differences in mRNA levels. The reason for this
discrepancy remains to be elucidated, but probably depends on
post-transcriptional regulation of TNF-R1 expression.
Several proinflammatory mediators are upregulated in myo-
tubes upon TNF-a challenge [15,24] and in muscle wasting
disorders [24,37]. In line with this, we found a significant increase
in the expression of selected NF-kB-dependent target genes in
C2C12 cells treated with TNF-a. Interestingly, we observed that
isoproterenol treatment by itself did not significantly affect the
expression of these genes, but potently enhanced TNF-a-induced
expression of a subset of inflammatory factors, such as IL-6 and
CXCL5, and to a lesser extent that of CCL2 and ICAM-1,
whereas that of others (CCL5 and IkBa) remained unaffected.
The regulation of IL-6 expression was investigated previously in
C2C12 cells stimulated with lipopolysaccharide (LPS) and
epinephrine [13]. Similar to what we observe here using TNF-a
as a proinflammatory stimulus, the authors reported synergistic IL-
6 expression upon LPS/epinephrine cotreatment, indicating the
synergy depends on a signalling protein that is common to TNF-R
and Toll-like receptor (TLR) pathways. As opposed to previous
Figure 6. C2C12 myotubes secrete factors that promote the migration of C2C12 myoblasts. C2C12 myotubes were treated for 24 hours
with veh, iso and/or TNF. Conditioned medium was prepared as described in Materials and Methods and applied to C2C12 myoblasts. Recombinant
IGF-1 was used as a positive control. Cell migration was monitored for 24 hours. (A) Selected start and end phase contrast images for the different
conditions from a representative experiment. The red line delineates the confluent cell layer that migrates inwards in time; arrows show migration
direction into the cell-free zone. (B) Cell-covered area over time plot from a representative experiment. The lines represent the mean area for
technical replicates (n indicated in the Figure); error bars are SEM. (C) Mean migration velocity (n replicates, see data in B) for the tested conditions in
a representative experiment. (Relative migration efficiencies based on the cumulated data of three independent biological experiments are shown in
Figure S4). Error bars are SEM. Statistical analysis was performed using Wilcoxon pairwise comparison with Bonferroni correction for multiple testing.
(*) Significantly different from veh. (**) Significantly different from TNF. (***) Significantly different from iso.
doi:10.1371/journal.pone.0090649.g006
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reports of anti-inflammatory effects of b-agonists [10–12], we did
not find any evidence for that in C2C12 cells. The anti-
inflammatory effects of b-agonists have been mostly explained
by b2-AR-mediated upregulation of IkBa levels, either via
induction of its transcription, or by promoting its stability through
interaction with the GPCR adaptor b-arrestin [10,12,38]. In
C2C12 cells, we and others [13] did not detect any modulation of
IkBa mRNA or protein levels, indicating b2-AR-dependent
regulation of IkBa levels is a cell type-specific process. The lack
of effects on IkBa expression was confirmed by our observation
that isoproterenol cotreatment did not hamper nuclear transloca-
tion of NF-kB p65. In addition, we did not find potentiation of
TNF-a-induced MAPKs or MSK-1 activation by isoproterenol,
rather we found mild inhibition of MSK-1, ERK and JNK –
indicating the effect of isoproterenol cannot be explained by
cytoplasmic crosstalk with canonical TNF-a-induced signalling
cascades. Whereas Frost et al. [13] suggested that epinephrine
promotes activation of ERK, p38 and JNK MAPKs, we did not
find any evidence for that using isoproterenol as a stimulus.
Activation of these MAPKs by epinephrine in the publication by
Frost et al. was however solely supported by effects of pharmaco-
logical inhibitors on IL-6 expression.
The most important novel finding in this paper is the
observation that, in addition to IL-6, the expression of several
chemokine genes is potentiated upon TNF-a/isoproterenol
cotreatment of skeletal muscle cells. The genes we investigated
in this study all contain NF-kB responsive elements in their
proximal promoters. As is evident from Table S2, there is
significant variation in the sequences of these elements. Although
the investigated selection of genes is too small to make any reliable
predictions, it is noteworthy that the NF-kB consensus sequences
in the most responsive IL-6 (GGGATTTTCC) and CXCL5
(GGGAATTTCC) promoters bear the strongest similarity among
the investigated genes. Recently, Siggers et al. [39] performed a
comprehensive in vitro analysis of DNA binding by NF-kB dimers.
Using Siggers’ open source dataset, we evaluated whether the IL-6
and CXCL5 NF-kB sequences showed a particular preference for
selected NF-kB dimers, as compared to genes that were not prone
to TNF-a/isoproterenol coregulation, but could not find evidence
for that. In fact, the binding preference of the NF-kB sequence in
the IL-6 promoter resembled most that of the kB sequence in the
IkBa promoter, which was not susceptible to synergistic regulation
by TNF-a/isoproterenol. Evaluating whether the sequence of the
NF-kB responsive element determining for the response to
isoproterenol will however require more extensive, genome-wide,
analysis. In addition to specifying NF-kB dimer binding, the
sequence of the kB site also dictates which co-activators will bind
to a selected promoter, and accumulating evidence suggests NF-
kB dimers can adopt different conformations when bound to
different DNA sequences [40]. In line with this, even a single
nucleotide change within a kB sequence was shown to affect
cofactor specificity of NF-kB dimers [41]. Cofactor specificity is
also determined by post-translational modifications of NF-kB
family members. Interestingly, both PKA and MSK-1 have been
shown to phosphorylate p65 on its serine 276 residue, which
promotes its association with the CBP coactivator and selective
NF-kB dependent gene induction [42,43]. Because of the lack of
specific antibodies recognizing p65 phosphorylated at the serine
276 residue, we were unable to investigate whether this
phosphorylation is triggered in C2C12 cells upon activation of
PKA and/or MSK-1 [44]. We recently also reported synergistic
IL-6 expression in human 1321N1 astrocytes cotreated with TNF-
a/isoproterenol [26] indicating the TNF-R1/b2-AR synergy is not
a phenomenon restricted to C2C12 cells. Nevertheless, in
astrocytes we also detected inhibitory effects of isoproterenol (for
instance at the ICAM-1 gene), whereas in the current study
isoproterenol did not block the expression of any of the
investigated genes (including ICAM-1). Our results indicate that
the effects of isoproterenol are not only gene-selective, with only a
selection of NF-kB dependent genes being susceptible to
potentiation by isoproterenol, but that there is also an important
cell type-specific component determining the outcome of TNF-
R1/b2-AR co-activation. This cell-type specificity is supported by
other reports describing different effects of b-agonists on the
expression of selected inflammatory mediators, depending on the
cell type investigated [11,45,46].
Expression of NF-kB target genes is regulated at multiple levels
and selectivity is accomplished, among others, by co-operation of
multiple transcription factors and cofactors in so-called enhanceo-
some structures as well as by epigenetic mechanisms [47]. We
showed via chromatin accessibility assays that b2-AR/TNF-R co-
activation induces chromatin remodelling at the IL-6 promoter.
Both MSK-1 and PKA can directly phosphorylate histone H3 and
recruit chromatin-remodelling complexes leading to increased
promoter accessibility [31,32,48]. In agreement with this, we
observed that in C2C12 cells concurrent activation of MSK-1 and
PKA is associated with enhanced histone H3 phosphorylation and
chromatin relaxation at the IL-6 promoter. Whereas we cannot
exclude that there are also effects of the individual triggers (as is
indicated by detectable recruitment of p65, CREB, CBP and RNA
polymerase II also upon stimulation of cells with only isoproterenol
or TNF-a) that are below the detection limit of our assays, it is
clear that b2-AR/TNF-R co-activation promotes transcriptional
synergy.
Intriguingly, it was reported that at the c-fos promoter (in vitro)
CREB binding and phosphorylation are required to recruit MSK-
1, which then phosphorylates histone H3 [49]. Here, we observed
that, although both TNF-a and isoproterenol stimulate phosphor-
ylation of CREB on serine 133, CREB activation is only promoted
in the presence of isoproterenol. These results are in agreement
with previous reports demonstrating that both MSK-1 and PKC
phosphorylate CREB on serine 133 to a similar extent as PKA,
but that only PKA-mediated phosphorylation resulted in CREB-
dependent transcription [50,51]. According to the generally
accepted model for CREB-dependent transcriptional activation,
CREB is constitutively bound to its target gene promoters and
transcriptional activation requires phosphorylation of CREB. We
have attempted to immunoprecipitate phosphorylated CREB from
the IL-6 promoter using two antibodies that recognise CREB
phosphorylated at serine 133, but failed to recover it (data not
shown). Instead, we found that CREB was actively recruited to the
IL-6 promoter upon isoproterenol, but not upon TNF-a
treatment. We previously reported CREB recruitment at the IL-
6 promoter upon TNF/isoproterenol cotreatment in human
astrocytes [26]. These findings are moreover in line with other
reports demonstrating active CREB recruitment at selected gene
promoters. For instance, it has been shown that CREB
recruitment occurs at glucagon-responsive gene promoters in
hepatocytes treated with forskolin [52], at the c-fos promoter in
neurons treated with BDNF [53] and at the ICER promoter in
forskolin-treated PC12 cells [54].
We found that TNF-a induced CREB phosphorylation, but did
not promote activation of a CREB-dependent reporter gene and
did not induce CREB recruitment to the IL-6 promoter. It is,
however, possible that TNF-a-induced CREB phosphorylation
plays a role in the transcriptional activation of other genes,
perhaps requiring different CREB co-activators. Evaluating the
contribution of TNF-a induced MSK-1 versus isoproterenol-
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induced PKA in CREB-mediated gene transcription will, howev-
er, require further study.
In addition to phosphorylation, acetylation of histones plays a
crucial role in gene expression [27,28]. Moreover, combinations of
multiple histone modifications can reinforce the robustness of the
chromatin state and as a consequence modulate gene expression
[55,56]. We previously proposed that the selective synergy at the
IL-6 promoter in astrocytes was the result of co-operative
recruitment of the transcriptional coactivator CBP by CREB
and NF-kB, that are positioned in close proximity at the IL-6
promoter [26]. Interestingly, also the CXCL5 promoter contains a
CREB and NF-kB element in its proximal promoter, indicating
this could be a signature of genes susceptible to TNF-R1/b2-AR
co-activation. CBP acts as a transcriptional coactivator by either
acetylating histone tails via its intrinsic acetyl-transferase activity or
by recruiting additional histone acetyl-transferases (HATs), hence
promoting chromatin accessibility [57,58]. Surprisingly, whereas
CBP is efficiently recruited to the IL-6 promoter upon TNF-a/
isoproterenol cotreatment in the present study, we did not find
evidence for a positive role of histone acetylation in promoting
chromatin relaxation. This observation is in line with a previous
report showing reduced IL-6 expression in C2C12 cells treated
with TSA [13] and suggests the existence of cell-type specific
epigenetic regulatory mechanisms acting at the IL-6 promoter.
Importantly, whereas previous studies show coupling of histone
H3 phosphorylation and acetylation as prerequisite for transcrip-
tional activation [59,60], we could not find evidence for that in our
model system. It could be that, at the IL-6 promoter, CBP has a
function independent of its HAT activity. It is indeed well known
that CBP can acetylate non-histone proteins and in this way affect
transcriptional activity. For instance, it has been shown that CBP
acetylates CREB [61] and NF-kB p65 [62,63], and that these
modifications are instrumental for efficient transcriptional activa-
tion. Further experiments will however be required to investigate
whether this indeed occurs at the IL-6 promoter.
In conclusion, the most striking observation of this study is that
co-activation of the TNF-R1 and b2-AR potently enhances the
expression of a subset of inflammatory mediators in C2C12
skeletal muscle cells. Recent reports demonstrated that IL-6, as
well as C-C and C-X-C chemokines, regulate various stages of
skeletal muscle regeneration [33,64,65]. For example, IL-6,
CXCL5, CCL2 and CCL5 were shown to induce leukocyte influx
to remove damaged myofibers [24,65] and stimulate myoblast
migration to fill in damaged areas [33,64,66]. Here, we show that
cotreatment of myotubes with TNF-a and isoproterenol synergis-
tically promotes the secretion of factors that induce the migration
of undifferentiated myoblasts in vitro. In future studies, it would be
interesting to investigate how this affects the recruitment of satellite
cells and leukocytes in vivo, and in particular in models of TNF-a-
dependent muscle disease.
Based on our findings, we propose the following model
(Figure 7): in C2C12 myotubes (I) TNF-R activation promotes
Figure 7. Model describing signalling events that are associated with b2-AR/TNFR coactivation in C2C12 cells, ultimately leading to
transcriptional synergy at selected NF-kB-dependent promoters. For a detailed description we refer to the text in the discussion. Dotted
lines indicate connections that are based on correlations and hence should be interpreted as assumptions rather than proven facts.
doi:10.1371/journal.pone.0090649.g007
b-Agonists Modulate Skeletal Muscle Inflammation
PLOS ONE | www.plosone.org 12 March 2014 | Volume 9 | Issue 3 | e90649
activation of the canonical NF-kB signalling cascade and MAPKs,
including the downstream p38 MAPK target MSK-1, which can
phosphorylate CREB (II) b2-AR activation is associated with
activation of PKA, which is the canonical CREB kinase (III) b2-
AR activation does not interfere with early events in TNF-
triggered pro-inflammatory NF-kB and MAPK activation (IV) b2-
AR/TNF-R coactivation is associated with enhanced phosphor-
ylation of histone H3 and chromatin relaxation at selected gene
promoters (i.e. IL-6) and this is paralleled by recruitment of
CREB, NF-kB p65 and CBP transcriptional coactivators as well as
RNA polymerase II (V) TNF-R/b2-AR coactivation leads to
synergistic gene expression of selected pro-inflammatory mediators
and the secretion of factors that promote the migration of
undifferentiated myoblasts.
Finally, as we did not detect anti-inflammatory effects of b-
agonists in C2C12 skeletal muscle cells, but instead potentiation of
TNF-a action, we suggest caution in the proposed use of b-
agonists as therapeutic agents for inflammatory myopathies and
urge for further study.
Supporting Information
Figure S1 Myogenesis correlates with the expression of
myogenin (Myog) in C2C12 skeletal muscle cells. The basal
expression patterns of myogenin (Myog) mRNA (A) and protein
(B) were compared in C2C12 myoblasts versus myotubes using
RT-qPCR and Western blotting. For Western blotting, cells were
lysed in RIPA buffer. A representative blot from two independent
experiments is shown. (C) Confirmation of the b2-AR antibody
specificity. Increasing amounts of an expression plasmid encoding
a haemagglutinin-tagged b2-AR-HA (b2-AR-HA) was transiently
transfected in HEK 293T cells. Cells were lysed in SDS sample
buffer and analysed via Western blotting using a-b2-AR and/or a-
HA. A representative blot from two independent experiments is
shown.
(TIF)
Figure S2 Effect of b-agonist cotreatment on NF-kB-dependent
gene expression in C2C12 myotubes. Expression of muscle-
derived cytokines was measured by RT-qPCR after 2, 5 and 16-
hours induction with veh, iso and/or TNF in C2C12 myotubes.
Fold induction for each gene was calculated versus veh control at
the corresponding time point. Results represent average 6 SD of
three independent experiments.
(TIF)
Figure S3 Nuclear events associated with iso/TNF cotreatment.
(A) ChIP analysis of histone H3 acetylation. C2C12 cells were
treated with vehicle or iso/TNF for up to 2 hours. Kinetics of
histone H3 acetylation were determined via ChIP using an
antibody recognizing histone H3 acetylated at Lys 27. Results
represent average 6 SD of three independent experiments. (B)
TSA treatment promotes global histone H3 acetylation at Lys 27
in C2C12 cells. The efficiency of TSA in promoting histone
acetylation was checked via confocal microscopy using anti-acetyl
Lys 27 histone H3. The scale bar in the image equals 5 mM. The
experiment was performed three times and a representative image
is shown. (C–G) Control of ChIP assay gene specificity. Control
ChIP experiments showing specificity of the observed responses for
the IL-6 promoter. ChIP samples from the experiments shown in
Figure 5 were re-analyzed using primers amplifying the GAPDH
housekeeping gene promoter. Results represent average 6 SD of
three independent experiments. Statistical signifance was deter-
mined via ANOVA followed by Bonferroni’s multiple comparison
test. (*) Significantly different from veh. (**) Significantly different
from TNF. (***) Significantly different from iso. (H) ChIP aspecific
antibody background control. Control ChIP experiments com-
paring signals obtained using protein A beads only or aspecific
control antibodies (normal rabbit IgG or normal goat IgG) versus
signals obtained using selected specific antibodies (CREB and
p65). Cells were treated for 2 hrs with iso+TNF, which is the
optimal time point for detection of CREB and p65 recruitment.
Results represent average 6 SD of three independent experi-
ments.
(TIF)
Figure S4 C2C12 myotubes secrete factors that promote
migration of C2C12 myoblasts. C2C12 myotubes secrete factors
that promote the migration of C2C12 myoblasts. Relative
migration efficiency based on the cumulated data of three
independent biological experiments (total number of technical
replicates, n = 22,24,23,25,25 for veh, iso, TNF, TNF/iso and
IGF-1 respectively). Migration efficiency is a measure of the ratio
of the obtained velocity versus the one in ‘veh’ condition.
Statistical analysis was performed using Wilcoxon pairwise
comparison with Bonferroni correction for multiple testing. (*)
Significantly different from veh. (**) Significantly different from
TNF. (***) Significantly different from iso. The table shows p-
values indicating the result of pairwise comparison of the indicated
conditions. Only ‘TNF’ and ‘iso’ do not significantly differ in
migration efficiency (p.0.05).
(TIF)
Table S1 Summary of primer sequences used in the present
study.
(DOCX)
Table S2 Summary of the position and sequence of NF-kB
binding sites in the proximal promoters of selected genes.
(DOCX)
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